Eighty percent of the patients with molar pregnancy go into spontaneous remission and do not require any therapy. Serial hCG determinations can identify the 20% who will develop malignant sequelae. It does not seem appropriate to treat all patients. This study was designed to assess several serum markers, including free beta-hCG, total beta-hCG, and CA-125 in order to identify persistent trophoblastic disease. The study was performed at Doctor Zekai Tahir Burak Women's Hospital, Department of Oncology. Forty-seven patients with complete hydatidiform mole were included in the study. In the spontaneous remission group (Group I), total betahCG, CA-125 and free betahCG values were 27988.7+/-18491.6 mlU/ml, 51.7+/-74.7 U/ml and 42.35+/-28.4 mlU/ml, respectively. Patients in whom persistent trophoblastic disease had developed (Group II) the mean serum CA-125 and mean total betahCG values were lower than in group I, whereas the mean free betahCG value was higher but not significant. The mean value of free betahCG per total betahCG was found to be significantly higher in group 2. The free betahCG per total betahCG ratio seems to be a sensitive predictor of persistency of trophoblastic disease. Further prospective studies with a larger series of patients may warrant the exact predictive value of free betahCG per total hCG ratios.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Automatic Single-Cell Harvesting for Fetal Nucleated Red Blood Cell Isolation on a Self-Assemble Cell Array (SACA) Chip.
Micromachines (Basel)
December 2024
Department of Engineering and System Science, National Tsing Hua University, Hsinchu 30013, Taiwan.
(1) Background: Fetal chromosomal examination is a critical component of modern prenatal testing. Traditionally, maternal serum biomarkers such as free β-human chorionic gonadotropin (Free β-HCG) and pregnancy-associated plasma protein A (PAPPA) have been employed for screening, achieving a detection rate of approximately 90% for fetuses with Down syndrome, albeit with a false positive rate of 5%. While amniocentesis remains the gold standard for the prenatal diagnosis of chromosomal abnormalities, including Down syndrome and Edwards syndrome, its invasive nature carries a significant risk of complications, such as infection, preterm labor, or miscarriage, occurring at a rate of 7 per 1000 procedures.
View Article and Find Full Text PDFEarly Prediction of Gestational Diabetes Mellitus and Insulin Therapy Requirement Using First-Trimester PAPP-A and Free β-hCG MoMs Levels: A Retrospective Case-Control Study.
J Clin Med
December 2024
Department of Perinatology, University of Health Sciences Etlik Zübeyde Women's Health Care Training and Research Hospital, 06010 Ankara, Turkey.
To evaluate the association between gestational diabetes mellitus (GDM), including insulin-dependent GDM with pregnancy-associated plasma protein-A (PAPP-A) multiples of the median (MoM) and free beta human chorionic gonadotropin (free β-hCG) MoM levels, and to assess their potential as predictive risk factors. This retrospective study included 2588 women with singleton pregnancies who underwent combined first-trimester screening, along with the 50 g glucose challenge test (GCT) and a 100 g oral glucose tolerance test (OGTT) between 24 and 28 weeks of gestation. Patients were initially divided into four groups based on the glucose screening results, and PAPP-A and free β-hCG MoMs were compared between these groups.
View Article and Find Full Text PDFBeta-human chorionic gonadotropin, carbohydrate antigen 19-9, cancer antigen 125, and carcinoembryonic antigen as prognostic and predictive biological markers in bladder cancer.
Front Oncol
December 2024
Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.
Introduction: We evaluated the prognostic potential of the Beta-human chorionic gonadotropin (β-hCG), Carbohydrate Antigen 19-9 (CA19-9), Cancer Antigen 125 (CA125), and Carcinoembryonic Antigen (CEA) tumor markers for bladder cancer.
Methods: We analyzed the records of 369 patients who underwent radical cystectomy for urothelial cancer (UC) between October 2012 until December 2019. Levels of CA19-9, CA125, CEA, and β-hCG before radical cystectomy were measured in all patient samples, and serum biomarker cutoff values were used as normal and elevated values.
Comparison of pregnancy outcomes in amniocentesis recipients with normal and abnormal maternal serum analytes.
Cell Mol Biol (Noisy-le-grand)
November 2024
Reproductive Health Research Center, Department of Midwifery and Reproductive Health, Al-Zahra Hospital, Guilan University of Medical Sciences, Rasht, Iran.
Considering the relatively high frequency of genetic disorders associated with negative pregnancy outcomes, in this research, adverse pregnancy outcomes in amniocentesis patients were compared between two groups with normal and abnormal maternal serum analytes. This retrospective cohort study was conducted on singleton pregnant women who underwent amniocentesis and had fetuses with normal chromosomes at the perinatology clinic in Rasht. Eligible patients were divided into two groups of 307 people with normal and abnormal maternal serum analytes based on laboratory screening results.
View Article and Find Full Text PDFSerum β‑hCG as a prognostic marker for colorectal adenocarcinoma in women of reproductive age: A case report and literature review.
Med Int (Lond)
November 2024
Division of Gastroenterology, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Serological and histological examinations have unveiled the presence of free β subunit of human chorionic gonadotropin (β-hCG) in some cases of colorectal adenocarcinoma. The present study describes an unusual case of a young female patient afflicted with rapidly advancing adenocarcinoma of the sigmoid colon. Despite the absence of pregnancy indications on an ultrasound and curettage, a notable elevation of β-hCG was detected in the serum, alongside positive staining in the tumor tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!